NCT01570959View on ClinicalTrials.gov

Crossover Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets Under Steady State Fasted Conditions

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions

Bipolar I Disorder

Interventions

DRUG

Quetiapine Fumarate

300 mg tablet

Trial Locations (7)

33161

Segal Institute for Clinical Research, North Miami

77008

Claghorn-Lesem Research Clinic, Ltd, Houston

78754

Community Clinical Research, Inc., Austin

91950

Synergy Clinical Research Center, National City

92845

Collaborative Neuroscience Network, Inc., Garden Grove

08540

Global Medical Institutes/Princeton Medical Institute, Princeton

08046

CRI Worldwide, Willingboro

All Listed Sponsors

lead

Roxane Laboratories

INDUSTRY

NCT01570959 - Crossover Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets Under Steady State Fasted Conditions | Biotech Hunter | Biotech Hunter